BioCryst Pharma Q2 2024 GAAP EPS $(0.06) Beats $(0.18) Estimate, Sales $109.332M Beat $98.319M Estimate
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.06), beating the estimate of $(0.18). Sales were $109.332 million, surpassing the $98.319 million estimate.

August 05, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCryst Pharmaceuticals reported better-than-expected Q2 2024 results with a GAAP EPS of $(0.06) compared to the $(0.18) estimate and sales of $109.332 million versus the $98.319 million estimate.
The better-than-expected earnings and sales figures are likely to positively impact BioCryst Pharmaceuticals' stock price in the short term. Beating both EPS and sales estimates typically boosts investor confidence and can lead to a stock price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100